Publication details

Prognostic relevance of MYD88 mutations in CLL: the jury is still out

Investor logo
Authors

BALIAKAS Panagiotis HADZIDIMITRIOU Anastasia AGATHANGELIDIS Andreas ROSSI Davide SUTTON Lesley-Ann KMÍNKOVÁ Jana SCARFO Lydia POSPÍŠILOVÁ Šárka GAIDANO Gianluca STAMATOPOULOS Kostas GHIA Paolo ROSENQUIST Richard

Year of publication 2015
Type Article in Periodical
Magazine / Source Blood
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf
Doi http://dx.doi.org/10.1182/blood-2015-05-648634
Field Oncology and hematology
Keywords CHRONIC LYMPHOCYTIC-LEUKEMIA; GENES; SF3B1
Attached files
Description Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info